Vaxcyte, Inc.
(NASDAQ: PCVX)

Vaxcyte, Inc. engages in the development of vaccines for infectious diseases. It focuses on conjugate vaccines and protein-based vaccines developed through the Sutro Biopharma's Xpress CF Platform, a cell-free protein synthesis technology. The company was founded by Grant E. Pickering and Jeff Fairman on November 27, 2013, and is headquartered in San Carlos, CA.

52.820 -

+1.450 (+2.82%)
Range 51.200 - 52.880   (3.28%)
Open 51.520
Previous Close 51.370
Bid Price 50.090
Bid Volume 300
Ask Price 51.690
Ask Volume 3
Volume 572,994
Value 30,102,686
Remark -
Delayed prices. Updated at 30 Jan 2026 05:15.
Data powered by
View All Events


Loading Chart...

Please login to view stock data and analysis